Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Mirja Ruutu"'
Publikováno v:
Journal of Pediatric Urology. 10:545-549
Purpose To evaluate the efficiency of visual internal urethrotomies (VIUs) in pediatric patients. Patients and methods Thirty-four patients aged 0.2–16.3 years were treated with VIUs as a primary treatment for urethral stricture at our institution
Autor:
M. Pilar Laguna, Ziya Kirkali, Mirja Ruutu, Jean J.M.C.H. de la Rosette, Hendrik Van Poppel, Marco Oderda, Steven Joniau, Paolo Gontero
Publikováno v:
International Journal of Urology. 20:356-361
The incidence of small renal masses is increasing, as a result of the wide adoption of imaging exams. Their management, however, is complicated, especially in patients with decreased life expectancy or comorbidities. Approximately 20% of small renal
Autor:
Mirja Ruutu, Hsiu Hsi Chen, Anssi Auvinen, Matti Hakama, U H Stenman, Grace Hui Min Wu, Teuvo L.J. Tammela, Amy Ming Fang Yen, Paula Kujala
Publikováno v:
European Urology. 61:1011-1018
Background Population-based screening for prostate cancer (PCa) has used serum prostate-specific antigen (PSA) since the early 1990s. However, the efficacy could be affected by screening interval, age ranges of screening, attendance, and contaminatio
Autor:
Mirja Ruutu, Nina N. Nupponen, Greetta Joensuu, Akseli Hemminki, Timo Joensuu, Sari Pesonen, Juhani Collan
Publikováno v:
Acta Oncologica. 51:130-133
Prostate cancer recurrence after therapy with curative intent is often first detected as an increase in prostate-specific antigen (PsA) (“rising PsA syndrome”) which may occur years in advance of clinical recurrence, and may present on opportunit
Autor:
Anna Sankila, Ville Rantanen, Leif C. Andersson, Sari Jäämaa, Marikki Laiho, Mirja Ruutu, Kimmo Taari, Taija af Hällström, Karita Peltonen, Päivi Järvinen
Publikováno v:
The Prostate. 72:1060-1070
BACKGROUND Prostate and seminal vesicle are two similar hormone responsive human organs that differ dramatically in their cancer incidence. DNA damage response (DDR) is required for maintenance of genomic integrity. METHODS In this study we investiga
Autor:
Mirja Ruutu, Anna Bill-Axelson, Jan-Erik Johansson, Eva Johansson, Tommy Nyberg, Gunnar Steineck, Lars Holmberg
Publikováno v:
The Lancet Oncology. 12:891-899
Summary Background For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting. Treatments are associated with morbidity. Results for functional outcome and quality of life are rarely reported beyond 10
Autor:
Greetta Joensuu, Akseli Hemminki, Jorma Isola, Mirja Ruutu, Petri Nokisalmi, Juhani Collan, Timo Joensuu, Mauri Kouri, Patrick A. Kupelian, Sari Pesonen, Chandana A. Reddy
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 78:42-49
To estimate the safety and tolerability of daily administration of 250 mg of gefitinib given concurrently with three-dimensional conformal radiotherapy for patients with nonmetastatic prostate cancer.A total of 42 patients with T2-T3N0M0 tumors were
Autor:
Tuomas P. Kilpeläinen, Mirja Ruutu, Paula Kujala, Liisa Määttänen, Teuvo L.J. Tammela, Anssi Auvinen, Ulf-Håkan Stenman
Publikováno v:
International Journal of Cancer. 127:1699-1705
Screening for prostate cancer (PC) remains a controversial issue despite some new evidence on the mortality benefits of PC screening. We conducted a prospective, randomized screening trial in Finland to investigate whether screening decreases PC inci
Autor:
Mirja Ruutu, Ulf-Håkan Stenman, Teuvo L.J. Tammela, Hanna Malmi, Harri Juusela, Anssi Auvinen, Liisa Määttänen
Publikováno v:
BJU International. 106:472-477
Study Type – Decision analysis (patient preference) Level of Evidence 4 OBJECTIVE To evaluate attitudes to prostate cancer screening with prostate-specific antigen (PSA) of men who complied with offered screening and those who declined it within th
Autor:
Teuvo L.J. Tammela, Jorma Isola, Mirja Ruutu, Markus Mildh, Martti Ala-Opas, Tapio Visakorpi, Anssi Auvinen, Liisa Määttänen, Paula M. Martikainen, Tiina Luukkaala, Marita Laurila
Publikováno v:
International Journal of Cancer. 124:547-552
Prostate cancer aggressiveness was evaluated based on pathologic characterization of cases detected in the Finnish prostate cancer screening trial. The trial population consists of 80,458 men aged 55-67 years. A total of 32,000 men were randomized to